CN101405405A - 预测对治疗的应答的方法 - Google Patents

预测对治疗的应答的方法 Download PDF

Info

Publication number
CN101405405A
CN101405405A CNA2006800289513A CN200680028951A CN101405405A CN 101405405 A CN101405405 A CN 101405405A CN A2006800289513 A CNA2006800289513 A CN A2006800289513A CN 200680028951 A CN200680028951 A CN 200680028951A CN 101405405 A CN101405405 A CN 101405405A
Authority
CN
China
Prior art keywords
marker gene
leu
gly
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CNA2006800289513A
Other languages
English (en)
Chinese (zh)
Inventor
约阿希姆·默克斯
安德烈亚斯·斯特劳斯
格哈德·楚格迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101405405(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN101405405A publication Critical patent/CN101405405A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
CNA2006800289513A 2005-08-12 2006-05-24 预测对治疗的应答的方法 Withdrawn CN101405405A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05017663.5 2005-08-12
EP05017663 2005-08-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910204668A Division CN101705287A (zh) 2005-08-12 2006-05-24 预测对治疗的应答的方法

Publications (1)

Publication Number Publication Date
CN101405405A true CN101405405A (zh) 2009-04-08

Family

ID=35511140

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2006800289513A Withdrawn CN101405405A (zh) 2005-08-12 2006-05-24 预测对治疗的应答的方法
CN200910204668A Pending CN101705287A (zh) 2005-08-12 2006-05-24 预测对治疗的应答的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910204668A Pending CN101705287A (zh) 2005-08-12 2006-05-24 预测对治疗的应答的方法

Country Status (32)

Country Link
US (2) US7700299B2 (enExample)
EP (2) EP1915460B1 (enExample)
JP (1) JP2009504142A (enExample)
KR (2) KR20080034922A (enExample)
CN (2) CN101405405A (enExample)
AR (1) AR057323A1 (enExample)
AT (2) ATE539171T1 (enExample)
AU (2) AU2006281746B2 (enExample)
BR (1) BRPI0615001A2 (enExample)
CA (1) CA2616913A1 (enExample)
CL (1) CL2010000720A1 (enExample)
CR (1) CR9686A (enExample)
CY (1) CY1111612T1 (enExample)
DE (1) DE602006019265D1 (enExample)
DK (1) DK1915460T3 (enExample)
EC (1) ECSP088171A (enExample)
ES (1) ES2356066T3 (enExample)
HR (1) HRP20110171T1 (enExample)
IL (1) IL188923A0 (enExample)
MA (1) MA31549B1 (enExample)
MX (1) MX2008001926A (enExample)
NO (1) NO20080371L (enExample)
NZ (1) NZ565270A (enExample)
PL (1) PL1915460T3 (enExample)
PT (1) PT1915460E (enExample)
RS (1) RS51859B (enExample)
RU (2) RU2408735C2 (enExample)
SI (1) SI1915460T1 (enExample)
TW (1) TW200741010A (enExample)
UA (1) UA93989C2 (enExample)
WO (1) WO2007019899A2 (enExample)
ZA (1) ZA201102688B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103109185A (zh) * 2010-04-18 2013-05-15 耶达研究及发展有限公司 用于治疗ErbB/ErbB配体相关疾病的分子和使用所述分子的方法
CN108753942A (zh) * 2011-10-06 2018-11-06 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
IL152656A0 (en) 2000-05-19 2003-06-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
AU2005287404B2 (en) 2004-07-22 2009-05-07 Genentech, Inc. HER2 antibody composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
MX2007008768A (es) * 2005-01-21 2007-10-19 Genentech Inc Dosificacion fija de anticuerpos her.
CN103251946A (zh) * 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
PE20090681A1 (es) * 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
JP5433189B2 (ja) * 2007-09-28 2014-03-05 承一 尾崎 Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
US10416162B2 (en) * 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
EP2237792B1 (en) * 2007-12-26 2017-05-24 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US9879267B2 (en) * 2008-03-14 2018-01-30 Genentech, Inc. Genetic variations associated with drug resistance
AU2009246398A1 (en) * 2008-05-14 2009-11-19 Bristol-Myers Squibb Company Predictors of patient response to treatment with EGF receptor inhibitors
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
EP2387717B1 (en) * 2009-01-15 2014-12-10 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-2 expression
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
AU2012204162B2 (en) * 2011-01-07 2017-04-20 Anji Pharmaceuticals Inc. Chemosensory receptor ligand-based therapies
DK4403228T3 (da) 2011-10-14 2025-10-13 Hoffmann La Roche Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab
KR102231554B1 (ko) 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
KR102035879B1 (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
RU2737727C2 (ru) 2013-04-16 2020-12-02 Дженентек, Инк. Варианты пертузумаба и их аналитическая характеристика
US20160175401A1 (en) * 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
RU2020120593A (ru) 2014-04-25 2020-09-01 Дженентек, Инк. Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
WO2017014810A1 (en) * 2015-07-17 2017-01-26 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
EP3791891A1 (en) 2014-07-17 2021-03-17 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
ES2984592T3 (es) 2015-05-30 2024-10-30 Hoffmann La Roche Procedimientos de tratamiento de cáncer de mama metastásico no tratado previamente positivo para HER2
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN105403704A (zh) * 2015-12-31 2016-03-16 苏州市博纳泰科生物技术有限公司 Her-2的荧光免疫层析检测方法及试剂盒
EP3534948A1 (en) 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
AU2017387909A1 (en) 2016-12-28 2019-06-27 Genentech, Inc. Treatment of advanced HER2 expressing cancer
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
KR20230144110A (ko) 2017-03-02 2023-10-13 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
KR20190140952A (ko) 2017-04-24 2019-12-20 제넨테크, 인크. 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
MY199134A (en) * 2018-05-25 2023-10-17 Bioneer Corp Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis related diseases and respiratory diseases, comprising same
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
WO2024036234A1 (en) * 2022-08-09 2024-02-15 Heligenics Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6759217B2 (en) * 1996-03-26 2004-07-06 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
JP2001504326A (ja) 1996-10-18 2001-04-03 ジェネンテック インコーポレーテッド 抗ＥｒｂＢ２抗体
GEP20104998B (en) 1999-06-25 2010-06-10 Genentech Inc Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040248151A1 (en) 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
GB0215509D0 (en) 2002-07-04 2002-08-14 Novartis Ag Marker genes
EP2263691B1 (en) * 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
ES2246191T1 (es) * 2002-12-11 2006-02-16 Ventana Medical Systems, Inc. Metodo para predecir la respuesta a la terapia dirigida a her2.
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2004087887A2 (en) 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
KR101126560B1 (ko) 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US20060204966A1 (en) 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
WO2005047534A2 (en) 2003-10-28 2005-05-26 Bayer Healthcare Ag Methods and compositions for the response prediction of malig-nant neoplasia to treatment
TWM256978U (en) * 2004-04-02 2005-02-11 Nventec Appliances Corp Electronic device
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
RU2300111C2 (ru) * 2005-06-15 2007-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ прогнозирования течения заболевания раком молочной железы

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103109185A (zh) * 2010-04-18 2013-05-15 耶达研究及发展有限公司 用于治疗ErbB/ErbB配体相关疾病的分子和使用所述分子的方法
CN108753942A (zh) * 2011-10-06 2018-11-06 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答

Also Published As

Publication number Publication date
US20100112603A1 (en) 2010-05-06
ECSP088171A (es) 2008-03-26
NO20080371L (no) 2008-05-09
KR20110074921A (ko) 2011-07-04
CR9686A (es) 2008-02-20
AU2011202339A1 (en) 2011-06-09
AU2006281746B2 (en) 2011-06-23
SI1915460T1 (sl) 2011-04-29
WO2007019899A2 (en) 2007-02-22
HRP20110171T1 (hr) 2011-04-30
EP1915460B1 (en) 2010-12-29
ES2356066T3 (es) 2011-04-04
PT1915460E (pt) 2011-03-17
UA93989C2 (ru) 2011-03-25
WO2007019899A3 (en) 2007-04-05
ATE493514T1 (de) 2011-01-15
PL1915460T3 (pl) 2011-05-31
AR057323A1 (es) 2007-11-28
EP1915460A2 (en) 2008-04-30
WO2007019899A8 (en) 2010-08-05
DK1915460T3 (da) 2011-01-31
BRPI0615001A2 (pt) 2011-04-26
IL188923A0 (en) 2008-08-07
CL2010000720A1 (es) 2010-12-03
ATE539171T1 (de) 2012-01-15
RU2010115252A (ru) 2011-10-27
AU2006281746A1 (en) 2007-02-22
EP2196547B1 (en) 2011-12-28
DE602006019265D1 (de) 2011-02-10
KR20080034922A (ko) 2008-04-22
RU2408735C2 (ru) 2011-01-10
JP2009504142A (ja) 2009-02-05
US20070037228A1 (en) 2007-02-15
MA31549B1 (fr) 2010-08-02
US7700299B2 (en) 2010-04-20
EP2196547A1 (en) 2010-06-16
CY1111612T1 (el) 2015-10-07
NZ565270A (en) 2011-05-27
TW200741010A (en) 2007-11-01
RU2008108907A (ru) 2009-09-20
CA2616913A1 (en) 2007-02-22
RS51859B (sr) 2012-02-29
CN101705287A (zh) 2010-05-12
MX2008001926A (es) 2008-03-24
ZA201102688B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
CN101405405A (zh) 预测对治疗的应答的方法
Wiseman et al. Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival
US8129114B2 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
CN103140761B (zh) 贝伐单抗组合疗法用于治疗胰腺癌的血浆生物标志物
CA2605151A1 (en) Determination of responders to chemotherapy
HK1217093A1 (zh) 贝伐单抗组合疗法用於治疗乳腺癌的血浆生物标志物
JP2015502543A (ja) 乳癌治療向けベバシズマブ併用療法用血漿バイオマーカー
US8124331B2 (en) In vitro method to detect bladder transitional cell carcinoma
Quintela et al. Expression and prognostic value of EGFR in invasive breast cancer
HK1139711A (en) Method for predicting the response to a treatment
WO2006009875A1 (en) Methods of detecting ovarian cancer based on osteopontin
Bartlett et al. Molecular diagnostics for determination of HER2 status in breast cancer
WO2023190820A1 (ja) 抗ＣＫ２α抗体又はその断片
WO2007091328A1 (ja) 肺癌の治療方法
HK1181459B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Application publication date: 20090408